|
New patient survey highlights need for more action to help severe asthma patients gain control of their disease
|
19 June 2017 |
|
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
|
09 June 2017 |
|
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
|
02 June 2017 |
|
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
|
22 May 2017 |
|
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
|
17 May 2017 |
|
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
|
04 May 2017 |
|
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
|
24 April 2017 |
|
Novartis expands development programs for NASH through clinical collaboration with Allergan
|
18 April 2017 |
|
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
|
07 April 2017 |
|
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
|
22 March 2017 |